A carregar...
Targets of opportunity for precision medicine
In this issue of Blood, Schinke et al have identified a higher expression of CXCR2 in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) stem cells than in normal hematopoietic stem cells (HSCs) and demonstrated preclinical therapeutic proof of principle.(1)
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4432001/ https://ncbi.nlm.nih.gov/pubmed/25977578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-04-638270 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|